The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS

Antiphospholipid Syndrome in Pregnancy Clinical Trial

Official title:
TheValue of Placental Vascularization Indices and Placental Volume in Pregnancies With Antiphospholipid Syndrome for Prediction of Neonatal Outcome"

Status Recruiting

Clinical Trial Summary

Antiphospholipid antibodies are autoantibodies directed against phospholipid‐binding proteins. Among these groups of antibodies, lupus anticoagulant (LA) and anticardiolipin antibodies (aCL)

Clinical Trial Description

APLS can be primary when no evidence of autoimmune disease is found, or secondary to autoimmune processes like systemic lupus erythematous (SLE) in a 40% of the cases. ;

Study Design

Related Conditions & MeSH terms

Antiphospholipid Syndrome
Antiphospholipid Syndrome in Pregnancy
Neovascularization, Pathologic
Syndrome

Clinical Trial Details

NCT number	NCT03505840
Study type	Observational
Source	Aljazeera Hospital
Contact	Mahmoud Alalfy
Phone	01002611058
Email	mahmoudalalfy@ymail.com
Status	Recruiting
Phase
Start date	April 24, 2018
Completion date	October 10, 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03100123` - AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study	Early Phase 1
Recruiting	`NCT03152058` - IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy	Phase 2
Recruiting	`NCT04275778` - HYDROxychloroquine in Syndrome Primary AntiPhospholipid	Phase 2
Recruiting	`NCT05378516` - Placental Pathology and Inflammatory Factor Analysis of OAPS
Recruiting	`NCT05679206` - Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure
Withdrawn	`NCT04274803` - Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?	Phase 4